saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription

Victoria Portnoy1, *, Szu Hua Sharon Lin1, *, Kathy H Li3, Alma Burlingame3, Zheng-Hui Hu1, Hao Li4, Long-Cheng Li1, 2

1Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA; 2Laboratory of Molecular Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China; 3Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA; 4Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94158, USA

Small activating RNAs (saRNAs) targeting specific promoter regions are able to stimulate gene expression at the transcriptional level, a phenomenon known as RNA activation (RNAa). It is known that RNAa depends on Ago2 and is associated with epigenetic changes at the target promoters. However, the precise molecular mechanism of RNAa remains elusive. Using human CDKN1A (p21) as a model gene, we characterized the molecular nature of RNAa. We show that saRNAs guide Ago2 to and associate with target promoters. saRNA-loaded Ago2 facilitates the assembly of an RNA-induced transcriptional activation (RITA) complex, which, in addition to saRNA-Ago2 complex, includes RHA and CTR9, the latter being a component of the PAF1 complex. RITA interacts with RNA polymerase II to stimulate transcription initiation and productive elongation, accompanied by monoubiquitination of histone 2B. Our results establish the existence of a cellular RNA-guided genome-targeting and transcriptional activation mechanism and provide important new mechanistic insights into the RNAa process.

Keywords: RNAa; promoter; transcription; RNAP II; Argonaute; Ago2; saRNA; promoter-targeted RNA; RITA

Cell Research (2016) 26:320-335. doi:10.1038/cr.2016.22; published online 23 February 2016

Introduction

Transcription is the first step to producing gene products and also a major control point for regulating gene expression. It is now known that most genes experience transcription initiation even when they are not being actively expressed [1, 2]. In such cases, transcription is curtailed due to promoter proximal pausing of RNA polymerase II (RNAP II) and failure of productive elongation [1, 2]. Thus, promoter proximal pausing is a rate-limiting step and also a target for manipulating gene expression [3]. Many strategies based on the use of DNA or RNA oligonucleotides and peptide nucleic acid have been tested in efforts to achieve targeted regulation of gene transcription [4-6]. However, so far, attaining sequence-specific and effective transcriptional manipulation has remained a challenge.

Small double-strand RNAs (dsRNAs) can trigger an evolutionarily conserved posttranscriptional gene silencing mechanism known as RNAi [7]. Transcriptional and epigenetic modulation of gene expression guided by small RNAs has also been unveiled, including transcriptional/epigenetic gene silencing (TGS) [8-12] and activation (RNAa) [13-18]. In these phenomena, the function of almost all small RNAs depends on members of the highly evolutionarily conserved Argonaute protein family, which consists of the Ago and Piwi subfamilies and serves as an RNA-programmable homology search engine [19].

Whereas TGS has been well characterized in several lower eukaryotes such as fission yeast and Drosophila [20, 21], the molecular mechanism for dsRNA-induced RNAa in mammalian cells remains poorly understood.
RNAa involves targeting of select sequences in gene promoters by short dsRNAs, also known as saRNA (small activating RNA), and has been demonstrated in mammalian species [13, 14, 22-24]. Surprisingly, RNAa also depends on Ago2 [13, 22, 24, 25], a core component of the RNA-induced silencing complex (RISC). It is believed that, in RNAa, Ago2 fulfills the same function as in RNAi, namely initial RNA duplex loading and strand processing [22, 25, 26]. Nevertheless, RNAa seems to possess unique kinetics characterized by a 24 h to 48 h delay in the onset of gene induction and its prolonged persistence thereafter [13, 14, 22], suggesting that RNAa is likely a phenomenon distinct from RNAi. Despite the demonstrated potential of RNAa both as a research tool [27, 28] and therapeutics [24, 29-31], generalized and efficient use of RNAa has been hindered by a lack of understanding of its detailed mechanism. Questions concerning how transcription is induced in RNAa, what other proteins besides Ago2 are required, and how saRNA binds to its target sequence at promoters remain unanswered.

In the present study, we performed detailed biochemical, proteomic and functional analysis using a saRNA-inducible gene, CDKN1A (p21), as a model. We provide concrete evidence that Ago2-loaded saRNAs strongly associate with their intended promoter targets, indicative of an RNA-guided genome-targeting mechanism. We further show that the saRNA-Ago2 complex interacts with RNAP II to stimulate both the initiation and elongation steps of transcription. We unveil critical components of the RNA-induced transcriptional activation (RITA) complex, which comprises at least saRNA-loaded Ago2, RHA and CTR9. Together, our results provide further support for, and new insights into, an RNA-guided and Ago2-dependent gene activation mechanism.

Results

RNAa occurs at the transcriptional level of gene regulation and is an “on-target” effect

Previous chromatin immunoprecipitation (ChIP) analyses revealed enrichment of RNAP II and association of specific epigenetic marks such as methylation of histone 3 at lysine 4 (H3K4) at saRNA target promoters [25, 32-34]. These observations argue for a transcriptional mechanism of gene induction by saRNAs. To determine the transcription rate of saRNA-inducible genes, we performed nuclear run-on (NRO) assays using two previously identified saRNAs, saP21 and saEcad, which induce expression of the p21 and E-cadherin genes, respectively [13]. saP21 and saEcad target the p21 and E-cadherin promoters at –322 and –215 relative to each gene’s transcription start site (TSS; Figure 1A and Supplementary information, Table S1). We transfected the saRNAs or a control dsRNA (saControl) into PC-3 cells (prostate carcinoma) and harvested the transfected cells for nuclei isolation 48 h later. To isolate nascent transcripts, we performed the NRO reaction in the presence of 5-bromouridine 5-triphosphate (BrUTP) followed by immunoprecipitation and affinity purification of BrUTP-labeled RNA transcripts. Purified NRO RNA was reverse transcribed and analyzed by quantitative RT-PCR (RT-qPCR) using primers that amplify the 5’ end of either p21 or E-cadherin mRNA (Figure 1A). Compared with mock transfection, we detected significantly higher levels of nascent transcripts for both the p21 and E-cadherin genes in cells transfected with the corresponding saRNAs. As shown in Figure 1B and 1C, saP21 and saEcad caused a 9.3- and 28.3-fold increase in BrUTP-labeled nascent p21 and E-cadherin transcripts, respectively, relative to mock transfection. Transfection with saControl did not significantly alter the transcription rate of either gene (Figure 1B and 1C). These results indicate that RNAa occurs at the transcriptional level to increase transcription rates and is largely independent of an effect on mRNA stability, as measured by mRNA decay kinetics (Supplementary information, Figure S1).

Small duplex RNAs are known to trigger sequence-specific and nonspecific off-target effects. To exclude the possibility that RNAa is an off-target effect, we used the CRISPR technique to mutate the saP21 target on the p21 promoter and obtained a subline of PC-3 cells (A-D7), which carried a 12- and 13-nt deletion in each of the two alleles within the saP21 target site (Figure 1D-1F). In wild type PC-3 cells (WT), saP21 induced p21 mRNA expression in a dose-dependent manner, whereas mutation of saP21 target in A-D7 cells almost abolished p21 mRNA induction by saP21 at all concentrations (Figure 1E). Western blotting analysis revealed that saP21 was still able to stimulate p21 protein level in A-D7 cells, but to an extent much less than that in WT cells (Figure 1F). The p21 protein induction by saP21 in A-D7 cells seemed to have occurred at the translational or post-translational levels through a mechanism unrelated to RNAa (Supplementary information, Data S1). These results indicate that the p21 promoter-targeted saRNA is able to induce p21 transcription through an on-target effect.

RNAa induces both transcription initiation and elongation

To further understand at which step of transcription RNAa acts, we determined the binding profile of RNAP II and the phosphorylation status of RNAP II C-terminal
domain (CTD) at serine 5 (Ser5) and serine 2 (Ser2) in response to saP21 treatment. RNAP II CTD phosphorylated at Ser5 and Ser2 corresponds to a pausing and elongating polymerase respectively. To accomplish this, we performed scanning ChIP assays on the \textit{p21} gene using antibodies that recognize either the initiating (non-phosphorylated) form of RNAP II or the phosphorylated RNAP II at CTD residues Ser5 (Ser5P) or Ser2 (Ser2P). A scanning ChIP assay for Ago2 was also performed. The resulted ChIP DNA was amplified by quantitative PCR (ChIP-qPCR) using six sets of primers in \textit{p21} gene ranging from −1.6 kb to +5.4 kb relative to \textit{p21} TSS (Figure 2A). A further upstream primer set (−3 861/−3 777) served as a control for background binding (Figure 2A). As shown in Figure 2B, in saP21-transfected cells, a significant enrichment of Ago2 binding was detected in a region (−417/−1) surrounding the saP21 target site with its peak centered on saP21 target, suggesting specific Ago2 binding guided by saP21. Further, RNAP II ChIP showed that, in mock-treated PC-3 cells, there was a minimal enrichment of the initiating RNAP II surrounding the TSS (Figure 2C, black line); however, upon saP21 treatment, we observed a massive increase in RNAP II binding surrounding the saRNA target site and the core promoter of \textit{p21} gene (Figure 2C, red line), consistent with the increased transcription rate from the \textit{p21} promoter as measured in the NRO experiments (Figure 1B) and increased Ago2 binding at the same location (Figure 2B). This result suggests that saRNA-Ago2 targeting of promoters may facilitate formation of the transcription initiation complex by associating with the initiating form of RNAP II and possibly by contributing to stabilization of the complex. Next, scanning ChIP analysis of RNAP II Ser5P and Ser2P found localized RNAP II Ser5P accumulation surrounding the TSS, but not in the gene body, in both mock- and saP21-treated cells (Figure 2D). In contrast, RNAP II Ser2P accumulation at the \textit{p21} gene in mock-treated cells was moderate (Figure 2E, black line), indicating potential promoter pausing and the absence of productive transcription elongation under non-RNAa conditions. Upon saP21 treatment, however, we observed significantly higher accumulation of RNAP II Ser2P starting from the 5′ end of and extending throughout the transcribed region of \textit{p21} (Figure 2E, red line).
Furthermore, the abrupt increase in RNAP II Ser2P accumulation at the 5′ end (Figure 2E) of \textit{p21} gene coincides well with the sharp decline of RNAP II Ser5P at the same position (Figure 2D), reflecting a transition in response to saP21 treatment from RNAP II pausing (Ser5P) at the TSS to RNAP II elongating (Ser2P) across the gene. Together, our results suggest that saRNA-guided Ago2 binding to promoter can stimulate both transcription initiation and productive elongation.

Development of the chromatin isolation by biotinylated RNA pull-down assay

To address several important mechanistic questions related to RNAa, including whether saRNAs actually bind to their intended targets on promoters, which saRNA strand is the guide or activator, and which protein factors participate in RNAa, we developed a ChIP-based assay which we called chromatin isolation by biotinylated RNA pull-down (ChIbRP). ChIbRP allows us to isolate DNA and protein components in the context of target chromatin associated with an saRNA (Figure 3A). This technique can also provide important information about saRNA loading by Ago2. In ChIbRP assay, an saRNA duplex is biotinylated at the 3′ end of one of the strands and transfected into cells. Following standard formaldehyde crosslinking, chromatin isolation and sonication, the chromatin is precipitated using magnetic streptavidin beads. After washing, nucleic acids or proteins associated with the biotinylated RNA are eluted from the beads, purified, and used in downstream analyses. Since previous studies have shown that Ago2 loading of duplex RNAs can be impaired by the addition of chemical groups such as biotin to the 5′ end of the guide strand, but not to the 3′ end [22, 35, 36], we added a biotin group to the 3′ end of either the sense or antisense strand of saP21, saEcad and saControl (Supplementary information, Table S1) and named the sense- and antisense- labeled duplexes as Bio(S) and Bio(AS) respectively. We first determined RNAa activity of these 3′-biotinylated saRNA duplexes by transfecting them individually and evaluating their target gene expression at the mRNA and protein levels. As shown in Figure 3B to 3D, compared with unlabeled saP21 and saEcad, duplex saP21 and saEcad 3′-biotinylated on either the sense or antisense strand had almost equivalent RNAa activity in inducing, respectively, \textit{p21} (Figure 3B) and \textit{E-cadherin} (Figure 3C) mRNA and protein levels (Figure 3D), whereas the control saRNA had no effect on the expression of either gene. We also added a psoralen group to the 5′ end of the antisense strand of saP21-Bio(AS) (Supplementary information, Table S1). However, the 5′ psoralen labeling of saP21-Bio(AS) abolished its activity in inducing \textit{p21} expression (Supplementary information, Figure S2A and S2B) by blocking Ago2 loading (Supplementary information, Figure S2C). These results confirm that attaching a biotin group to the 3′ end of either strand of a duplex saRNA does not affect its ability of triggering RNAa, whereas 5′ end labeling prevents Ago2 from loading the duplex and abolishes its RNAa activity.

\textit{Ago2-loaded saRNA associates with its intended target promoter DNA and interacts with RNAP II}

Having demonstrated that saRNAs tolerate 3′ biotinylation, we next applied ChIbRP assay using biot-
Figure 3 Chromatin isolation by biotinylated RNA pull down (ChIbRP) assay. (A) Flowchart of ChIbRP assay. A biotin group was attached to the 3′ end of either strand in an saRNA duplex, resulting two duplex versions (Bio(S) and Bio(AS)). The duplexes were individually transfected into cells which were treated, 48 h later, with formaldehyde to crosslink chromatin DNA/protein complexes. Chromatin was purified and associated DNA sheared by sonication. Chromatin complexes associated with the biotinylated saRNA were isolated with magnetic streptavidin beads. DNA and protein fractions were eluted for further analysis. W.B., western blotting. (B, C) RT-qPCR quantification of p21 (B) and E-cadherin (C) mRNA expression. saRNA targeting either the p21 or E-cadherin promoter was biotinylated at the 3′ end of either the sense [Bio(S)] or antisense [Bio(AS)] strand of the duplex, and transfected into PC-3 cells for 48 h. Data represent the means ± SD of at least two independent experiments and are plotted as fold changes relative to mock transfection. (D) Immunoblotting analysis of p21 and E-cadherin protein levels in cells transfected as in B. Detection of α-tubulin protein levels served as a protein loading control.
Figure 4 Ago2 loading of saRNA strands and their association with promoter DNA and interaction with RNAP II. (A, B) Schematic of the promoter region of the p21 (A) and E-cadherin (B) promoters studied by ChIbRP. Locations of the saRNA target, primer binding sites and transcription start site (TSS) on the promoter are shown. Three sets of primers were designed to analyze enriched DNA for each promoter, including primers that amplify the saRNA target region (Target F/R), intergenic region (“Intergenic F/R”), and regions close to the TSS (“5′ end F/R” for p21, and “TSS F/R” for E-cadherin). (C, D) Duplex saRNA sequence for saP21 (C) and saEcad (D) with calculated terminal ∆G values at 37 °C shown below the sequences. AS, antisense. (E, F) Strand-specific association of saP21 (E) and saEcad (F) with Ago2 detected by ChIbRP immunoblotting. PC-3 cells were transfected with the indicated duplex saRNAs for 48 h. The protein fraction of ChIbRP samples was used to detect Ago2 by immunoblotting. Bio(S) and Bio(AS), a biotin group was added to the sense and antisense strand respectively (see Materials and Methods section). (G, H) Strand-specific DNA association with saP21 (G) or saEcad (H) detected by ChIbRP qPCR. The DNA fraction from cells transfected as in E or F was used to amplify the DNA target region of the saRNAs using “Target F/R” primers or primers for control regions. Data represent the means ± SD of at least two independent experiments and are plotted as % of input. (I, J) ChIbRP detection of RNAP II protein in association with saP21 (I) or saEcad (J). ChIbRP-retrieved proteins were subject to immunoblotting of RNAP II.
explained by the different thermodynamic properties of their termini. For duplex saP21, which has an asymmetric terminal thermodynamic stability with a calculated 5′ end $\Delta G^\circ_5$ (kcal/mol) equal to −0.83 compared with 3.44 for its 3′ end (Figure 4C), Ago2 was mainly associated with the antisense strand (Figure 4E). In contrast, saEcad is almost symmetric in its terminal stability (Figure 4D), and, as a result, the two strands showed equal Ago2 association (Figure 4F). Surprisingly, we found no detectable Ago2 association of either strand of saControl (Figure 3E), which does not have any known target in the cells. Because in ChIbRP assay the chromatin-enriched fraction is isolated, the lack of Ago2 association for saControl can perhaps be attributed to its lack of targets in the nucleus. In this regard, a previous study has shown that only dsRNAs with a nuclear target could localize in the nuclear compartment [38].

By mutation assay, we have shown that an intact saP21 target in p21 promoter is required for RNAa activity (Figure 1D-1F). To further assess whether each Ago2-loaded guide saRNA strand binds to its intended promoter target sequence, we transfected cells with biotinylated duplex saRNAs and probed for DNA in the ChIbRP pull-down DNA fraction by qPCR using primer pairs designed to amplify the target region (“Target F/R”) of each saRNA and two genomic control regions, including regions close to the TSS (“TSS F/R” or “5′ end F/R”) and upstream intergenic regions (−3 000 bp, “Intergenic F/R”; Figure 4A). We observed a 24.7-fold enrichment in the amount of target DNA retrieved by the antisense strand of saP21 (saP21-Bio(AS)) relative to the intergenic control region, suggesting strong association of the antisense strand with target DNA (Figure 4G). However, DNA retrieved by saP21-Bio(S) was not enriched in any PCR amplicon region (Figure 4G), suggesting that no binding event for saP21-Bio(S) had occurred. In contrast, for saEcad, whose two strands have equal Ago2 loading (Figure 4F), we detected 16.8- and 14.8-fold enrichment in the DNA retrieved by the saEcad-Bio(S) and saEcad-Bio(AS) strands, respectively, at their target locations (Figure 4H). In addition, we used the two versions of saP21 and saEcad as cross controls for each promoter, and did not detect any binding at the saP21 target site by saEcad (saEcad-Bio(S) and saEcad-Bio(AS); Figure 4G) nor at the saEcad target site by saP21 (saP21-Bio(S) and saP21-Bio(AS); Figure 4H). The observed significant enrichment of target promoter DNA retrieved by Ago2-loaded saRNA guide strands strongly suggests that saRNAs bind to their intended targets at gene promoters in a sequence-specific manner. Consistent with their Ago2-loading patterns, only saRNA strands loaded by Ago2 were able to associate with target DNA (compare Figure 4E and 4G with Figure 4F and 4H). This points to the possibility that most, if not all, chromosome-targeted dsRNAs could guide Ago2 to its target site as long as it can program Ago2, supporting the view that Ago2 is a RNA-programmable homology search and binding protein [19]. This finding also raises an intriguing question: which saRNA strand provides RNAa activity if both strands can be loaded by Ago2 and bind to the promoter target as in the case of saEcad? Given that our previous study showed by sequence mutation and Ago2 blocking analysis that the antisense strand of saEcad is likely the activator strand [13, 22], the two strands of saEcad may not have equal RNAa activity even though both are capable of guiding Ago2 to the promoter target and interact with RNAP II (Figure 4H).

As our results showed an increased rate of transcription upon saRNA treatment (Figure 1B and 1C), we further investigated the potential interaction of the saRNA-Ago2 complex with the transcription machinery upon binding of the latter to promoters. We addressed this question by detecting RNAP II in the protein fraction of ChIbRP samples from cells transfected with biotinylated duplex saRNAs. As shown in Figure 4I and 4J, the AS strand in saP21 (Figure 4I) and both the S and AS strands in saEcad (Figure 4J) were able to associate with RNAP II, exhibiting a similar strand specificity found for Ago2 loading. Together, these findings clearly indicate that saRNAs predictably bind to their promoter targets in an Ago2-dependent manner and interact with the transcription machinery.

Identification of protein components of RNAa effector complexes

Having identified that the Ago2-loaded antisense strand of saP21 guides Ago2 to its promoter target where the saRNA-Ago2 complex interacts with RNAP II, we next examined what additional proteins are recruited by the saRNA-Ago2 complex to facilitate the Ago2-RNAP II interaction and transcriptional activation. To this end, we transfected cells with biotinylated saP21 for 48 h and applied the ChIbRP assay to the nuclear fraction pulled down with either saP21-Bio(S) or saP21-Bio(AS) and subjected the associated proteins to mass spectrometry (MS) analysis after protein separation by SDS-PAGE. Proteins pulled down by saP21-Bio(S), the passenger strand, served as a control for background proteins. Immunoblotting analysis of the prepared nuclear fraction revealed it to be free of cytoplasmic protein contamination (Supplementary information, Figure S3). MS analysis identified 42 proteins to be associated with saP21-Bio(AS) and only 15 with saP21-Bio(S) (Supplementary information, Figure S4, Table S2). Of the 42 proteins, 27
were uniquely associated with the guide strand saP21-Bio(AS) and the other 15 were shared by both strands (Supplementary information, Figure S4). Although Ago2 was recovered by both saP21-Bio(S) and saP21-Bio(AS), more Ago2 peptides were identified in the saP21-Bio(AS) sample \((n = 116)\) compared with saP21-Bio(S) sample \((n = 30)\). This finding is consistent with the ChIP-bRP results for the Ago2-loading pattern (Figure 3E) and further supports that the antisense strand of saP21 is preferentially loaded by Ago2 and serves as the functional (guide) strand. Among the 42 proteins associated with saP21-Bio(AS), there are additional dsRNA-binding proteins such as Ago3, Staun and ILF3, and proteins involved in RNA binding and splicing, including heterogeneous nuclear ribonucleoproteins (hnRNPs; Table 1). Of great interest are several of the proteins uniquely associated with the saP21 guide strand and known to be involved in RNA/DNA binding, transcriptional regulation and chromatin modification, including CTR9, RHA (also known as DHX9), ubiquitin B (UBB), histone H2A type 1-B/E (HIST1H2AB/E), poly(rC) binding protein 2 (PCBP2) and splicing factor proline/glutamine-rich (Table 1 and Supplementary information, Table S2). In addition, we identified translational, metabolic, ribosomal, cytoskeletal and chaperone proteins associated with saP21-Bio(AS) or both strands (Table 1). Surprisingly, RNAi-related proteins known as RISC-loading factors were absent from our list, including Dicer, TRBP and members of the TNRC6 family which are known to be almost invariably associated with Agos in human cells [39-41]. Of the identified proteins with a potential role in RNAa, we chose CTR9 and RHA as candidates for further validation since both proteins are known transcriptional activators with DNA/RNA-unwinding/binding activity and are potential interactors with RNAP II [42-45].

To validate the MS results and confirm physical interactions between each of the two candidate proteins (RHA and CTR9) and the two proteins (Ago2 and RNAP II) we already determined from earlier experiments to be either essential for RNAa (Ago2; Figure 3E and refs [13, 22]) or associated with the antisense strand of saP21 (RNAP II; Figure 4I), we first performed immunofluorescence staining of Ago2, RHA and CTR9. As expected, Ago2 is preferentially distributed in the cytoplasm, with scattered and punctate staining in the nucleus, whereas CTR9 and RHA almost exclusively reside in the nucleus (Supplementary information, Figure S5). We then conducted reciprocal co-immunoprecipitation assays. First, from the nuclear fraction (Supplementary information, Figure S3) of cells transfected with either saControl or saP21, we immunoprecipitated CTR9 or RHA using their specific antibodies. Ago2 and RNAP II were then detected by immunoblotting in the immunoprecipitated complexes. As shown in Figure 5A, CTR9 co-immunoprecipitated both Ago2 and RNAP II in cells transfected with saP21, but not saControl. Similarly, RHA co-immunoprecipitated both Ago2 and RNAP II in saP21 transfected cells; whereas in saControl transfected cells, minimal association of Ago2 and RHA was observed (Figure 5A). These results thus validated our MS findings and suggest a strong association between the saRNA-Ago2 complex and RHA, CTR9 and RNAP II. Since CTR9 is a component of a bigger complex, the PAF1 complex (PAF1C) known to interact with histone-modifying enzymes and RNAP II to regulate transcription, we assessed whether PAF1 protein was also present in the complex with CTR9 by detecting PAF1 in immunoprecipitates of CTR9 or RNA. As shown in Figure 5B, PAF1 was associated with CTR9, but not with RHA, in both saControl and saP21-treated cells (Figure 5B), suggesting that CTR9 and PAF1 form the known PAF1C. Further, we immunoprecipitated Ago2 in similarly treated cells and then probed for RHA, CTR9 and RNAP II. We found that RHA and CTR9 was uniquely co-immunoprecipitated with Ago2 in saP21- but not in saControl-transfected cells (Figure 5C). We also detected, in Ago2 immunoprecipitates, PAF1, RNAP II and PCBP2 (hnRNP E2), one of the major cellular poly(rC)-binding proteins involved in RNA binding (Table 1), and found that they were associated with Ago2 mainly in saP21-treated cells (Figure 5C).

To further test whether CTR9 is recruited to saRNA target site on promoters, we performed CTR9 ChIP in cells transfected with saP21 or saControl. No obvious enrichment of CTR9 was detected on p21 promoter in saControl-transfected cells, whereas in saP21-transfected cells, a significantly increased enrichment of CTR9 occurred surrounding the saP21 target site on promoters, we performed CTR9 ChIP in cells transfected with saP21 or saControl. No obvious enrichment of CTR9 was detected on p21 promoter in saControl-transfected cells, whereas in saP21-transfected cells, a significantly increased enrichment of CTR9 occurred surrounding the saP21 target site on p21 promoter and extended into the TSS region (Figure 5D). Together with the data shown in Figure 2B and Figure 5A-5C, this result suggests that CTR9 was recruited by the saRNA-Ago2 complex to the saRNA’s promoter target.

To confirm functional involvement of proteins identified by MS in RNAa, we examined the requirement of select candidate proteins for p21 activation. Specifically, we knocked down CTR9 and RHA by RNAi and determined whether p21 could still be activated by saP21. Knockdown of CTR9 (20% of mock; Figure 5E) and RHA (3% of mock; Figure 5F) significantly impaired the RNAa activity of saP21 as assessed at both the mRNA (Figure 5G and 5H) and protein (Figure 5I and 5J) levels of p21 expression. We also examined the requirement of CTR9 in the activation of KLF4 and E-cadherin by their saRNAs. As shown in Supplementary information, Figure S5.
Table 1 Proteins associated with saP21 identified by MS following ChlBRP

| Accession# | Gene Symbol | Protein Name | saP21-Bio(S)* | saP21-Bio(AS)* | Unique to Bio(AS) |
|------------|-------------|--------------|---------------|----------------|------------------|
| O95793     | STAU1       | dsRNA-binding protein Staufen homolog 1 | 2             | 4              |                  |
| Q12906     | ILF3        | Interleukin enhancer-binding factor 3 | 4             | 18             |                  |
| Q5STA56    | EIF2C3      | Eukaryotic translation initiation factor 2C, 3 | 2             | Yes            |                  |
| Q9UKV8     | EIF2C8      | Protein argonaute-2 | 18            | 44             |                  |

Nucleic acids binding/Splicing/Chromatin/Transcription

| P11940 | PABPC1 | Polyadenylate-binding protein 1 | 2             | 5              |                  |
| P22626 | HNRNPA2B1 | Heterogeneous nuclear ribonucleoproteins A2/B1 | 2             | Yes            |                  |
| Q31943 | HNRPNPH1 | Heterogeneous nuclear ribonucleoprotein H | 1             | Yes            |                  |
| P52272 | HNRNPMP | Heterogeneous nuclear ribonucleoprotein M | 2             | Yes            |                  |
| Q15366 | PCBP2 | Poly(rC)-binding protein 2 | 2             | Yes            |                  |
| P23246 | SFPQ | Splicing factor, proline- and glutamine-rich | 1             | Yes            |                  |
| Q6PD62 | CTR9 | RNA polymerase-associated protein CTR9 homolog | 1             | Yes            |                  |
| Q08211 | RHA | ATP-dependent RNA helicase A | 2             | Yes            |                  |
| P04908 | HIST1H2AB/E | Histone H2A type 1-B/E | 1             | Yes            |                  |
| P0CG47 | UBB | Polyubiquitin-B | 1             | Yes            |                  |
| P06748 | NPM1 | Nucleophosmin | 2             | 6              |                  |

Translation

| P60842 | EIF4A1 | Eukaryotic initiation factor 4A-I | 1             | Yes            |                  |
| P68104 | EEF1A1 | Elongation factor 1-alpha 1 | 3             | 2              |                  |

Metabolic proteins

| O00763 | ACACB | Acetyl-CoA carboxylase 2 | 1             | Yes            |                  |
| P06733 | ENO1 | Alpha-enolase | 1             | Yes            |                  |
| Q13085 | ACACA | Acetyl-CoA carboxylase 1 | 2             | 14             |                  |
| P04075 | ALDOA | Fructose-bisphosphate aldolase A | 5             | Yes            |                  |
| P14618 | PKM | Pyruvate kinase isozymes M1/M2 | 2             | 8              |                  |
| P00558 | PGK1 | Phosphoglycerate kinase 1 | 4             | Yes            |                  |

Chaperones

| P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | 5             | Yes            |                  |
| P08107 | HSPA1A/B | Heat shock 70 kDa protein 1A/1B | 1             | Yes            |                  |
| P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 6             | 9              |                  |

Cytoskeleton proteins

| A6NMY6 | ANXA2P2 | Putative annexin A2-like protein | 2             | Yes            |                  |
| P07355 | ANXA2 | Annexin A2 | 1             | 4              |                  |
| P04350 | TUBB4A | Tubulin beta-4 chain | 1             | Yes            |                  |
| P07437 | TUBB | Tubulin beta chain | 2             | 3              |                  |
| P18206 | VCL | Vinculin | 1             | Yes            |                  |
| P60709 | ACTB | Actin, cytoplasmic 1 | 12            | 17             |                  |
| Q15149 | PLEC | Plectin | 7             | Yes            |                  |
| Q5D862 | FLG2 | Filaggrin-2 | 2             | Yes            |                  |
| P21333 | FLNA | Filamin-A | 1             | Yes            |                  |
| P68363 | TUBA1B | Tubulin alpha-1B chain | 2             | 4              |                  |

Ribosomal proteins

| P08865 | RPSA | 40S ribosomal protein SA | 2             | 4              |                  |
| P15880 | RPS2 | 40S ribosomal protein S2 | 1             | Yes            |                  |
| P18124 | RPL7 | 60S ribosomal protein L7 | 1             | Yes            |                  |

Miscellaneous

| P01833 | PIGR | Polymeric immunoglobulin receptor | 2             | Yes            |                  |
| Q8IVZ3 | OSBPL1A | OSBPL1A protein | 1             | 1              |                  |
| P02808 | STATH | Statherin | 1             | Yes            |                  |

Total non-redundant proteins: 15 42

§For detailed listing of proteins recovered by MS, see Supplementary information, Table S2.

*Number of peptides for each unique protein associated with either saP21-Bio(S) or saP21-Bio(AS).
Figure 5 Characterization of the RNAa effector complex. (A) Association of Ago2 and RNAP II with CTR9 or RHA. PC-3 cells were transfected with the indicated saRNA for 48 h. Total protein extract from each treatment was immunoprecipitated with either anti-CTR9 or anti-RHA antibody. Effector proteins Ago2 and RNAP II were detected in the eluates by immunoblotting. (B) Association of PAF1 with CTR9. Proteins were immunoprecipitated using CTR9 or RHA antibodies as in A and probed for PAF1 by immunoblotting. (C) Association of Ago2 with RHA, PAF1, CTR9, PCBP2 and RNAP II. Reciprocal immunoprecipitation with anti-Ago2 antibody followed by immunoblotting detection of associated effector proteins. (D) Enrichment of CTR9 at saP21 target site. CTR9 ChIP was performed in PC-3 cells transfected for 48 h with saP21 or saControl. The immunoprecipitated DNA was amplified by qPCR using 4 sets of primers located at p21 promoter as indicated. The primer set at −3861/−3777 served as negative control for CRT9 binding. Results represent % of input in each experiment and are means ± SD of at least 3 independent experiments. (E-J) Knockdown of CTR9 and RHA impairs RNAa of p21. PC-3 cells were transfected with siRNA targeting CTR9 or RHA or control siRNA for 24 h, and the next day the cells were further transfected with saRNA for an additional 48 h. The transfected cells were then assessed by RT-qPCR for mRNA expression of CTR9 (E), RHA (F) and p21 (G, H), and by immunoblotting for protein expression of CTR9 (I), RHA (J) and p21 (I, J).
saRNA-Ago2 assembles RITA complex to induce transcription

saRNA targeting causes monoubiquitination of histone 2B

Histone 2B (H2B) ubiquitination is a histone modification that stimulates methylation of H3K4, leading to active transcription [46]. Since UBB polypeptide exists in the complex associated with saP21-Bio(AS) (Table 1), and PAF1C has been shown to induce monoubiquitination of histone 2B (H2Bub1), we decided to investigate the presence of H2Bub1 on p21 gene by ChIP using an antibody recognizing H2Bub1 in cells transfected for 48 h with saP21 (Figure 6A). Neither saP21 nor control treatments affected global H2Bub1 levels (Figure 6B). However, on p21 gene, we observed increased levels of H2Bub1 (compared with control treatments) starting from position −141 and continuing into the entire p21 transcribed region, with the enrichment ranging from 2.3- to 9.1-fold (Figure 6A). These data suggest that H2B ubiquitination could be an early event in the chain of transcriptional/epigenetic events that eventually lead to transcriptional activation of p21.

Discussion

Using the ChIbRP assay, which allows us to isolate and identify target-specific nucleic acids and proteins, we were able to address critical questions concerning RNAa. In the present work, we show that saRNAs are loaded by Ago2 and bind to their intended promoter targets, where Ago2 recruits RHA and CTR9 to interact with RNAP II, leading to ubiquitination of H2B and productive transcription elongation.

Central role of Ago2 in the RITA complex

Since the discovery of the essential role of Ago proteins in mediating posttranscriptional RNAi, surprising additional functions of Ago proteins, including roles in transcriptional regulation [47] and alternative splicing [41], have been uncovered. In these mechanisms, Ago proteins serve as an RNA-programmable recruitment platform which can be targeted by small RNAs to their cognate target molecules in both cytoplasmic and nuclear compartments, where Ago proteins then recruit diverse arrays of proteins of particular functions to influence dif-
Different aspects of gene regulation.

Several previous proteomic approaches have characterized proteins that form complexes with Ago proteins immunoprecipitated from either cytoplasmic or nuclear fractions [39-41, 48]. Commonly recovered proteins include components of the RISC-loading complex (e.g., Dicer, TRBP and TNRC6 family members), RNA helicases such as RHA, hnRNPs, splicing factors and histones. We used ChlbRP approach to pull down proteins associated with Ago2-loaded saRNA, and recovered categories of proteins common to those identified by Ago immunoprecipitation, thus validating our method as an effective alternative to Ago immunoprecipitation. More importantly, ChlbRP has the advantage of recovering not only general proteins associated with Agos, but also target-specific proteins associated only with the saRNA-Ago2 complex. Surprisingly, members of the RISC-loading complex are absent from the RITA complex, whereas proteins involved in transcriptional regulation such as CTR9 were identified for the first time in our analysis. Our findings suggest that Ago2, guided by a promoter-targeted saRNA, serves as a promoter-specific platform to recruit a unique set of proteins distinct from the RISC complex to form a RITA complex.

The RITA complex

Previous work using a candidate approach [49] or MS [34] identified several hnRNPs in association with saRNAs. By using ChlbRP, followed by MS analysis, we were able to identify hnRNPs (e.g., PCBP2) as well as additional factors such as RHA and CTR9 that form the RITA complex on the target promoter.

RHA, also known as nuclear DNA helicase II, is a member of the DEAH family of helicase superfamilly 2 and was first isolated from nuclei of calf thymus using a DNA-unwinding assay [50]. It contains two dsRNA binding domains, a helicase domain, and an RCG-rich region which possesses both RNA and DNA helicase activities [44, 51]. RHA directly binds to DNA or interacts with other transcription factors to mediate transcriptional activation by recruiting basal transcription machinery to promoter DNA and/or modifying chromatin structure [42, 43, 52-57]. RHA can also act as a bridging factor to recruit RNAP II into pre-initiation complexes [51, 55, 58]. Of particular interest, RHA can unwind triple-helical DNA structures in which the third strand contains a 3’ single-stranded overhang [42], a scenario similar to saRNA binding to dsDNA of a promoter. Although RHA has been shown to be a component of the RISC complex [59], it may play a critical role in RNAa given its nuclear localization and established functions in DNA unwinding and transcriptional activation. It is possible that RHA is both a general Ago2-interacting protein and an RNAa facilitator. Another interesting aspect of RHA is that the Drosophila homolog of RHA, known as maleless, is a component of the dosage compensation complex which is directed also by ncRNA to the male X chromosome to maintain upregulation of all genes on the chromosome [60, 61].

CTR9 is a component of PAF1C, which, in addition to PAF1, contains at least 4 other proteins (LEO1, CDC73, RTF1 and SKI8) [62, 63], and is involved in both transcription initiation and elongation [45, 64-67]. PAF1C is required to establish several histone modifications associated with active genes by recruiting histone-modifying factors such as E2/E3 ubiquitin ligase to the RNAP II complex to cause H2B ubiquitination and downstream H3K4 and H3K79 methylation [45, 62, 68]. PAF1C is also required for efficient phosphorylation of Ser2 of RNAP II CTD, suggesting it has a role in the transition between early and productive transcription elongation [67]. Similar to RHA, CTR9 has also been shown to bind a triple helix structure [69, 70]. The observed association of these two components of PAF1C (CTR9 and PAF1) with Ago2 suggests that components of PAF1C especially CTR9 may participate in RNAa.

The involvement of two proteins (RHA and CTR9) with DNA/RNA unwinding or binding activity is intriguing. Perhaps, such activity is needed for opening up the strands of the DNA duplex at the target site. The physical association of RHA and CTR9 with the guide strand and Ago2, and their function in DNA binding and unwinding in transcriptional activation, strongly suggest that they are bona fide components of the RITA complex.

Transcriptional and epigenetic activation by RNAa

A fundamental question regarding RNAa is how saRNAs stimulate transcription. saRNA and promoter-targeted miRNA have been shown to cause an enrichment of RNAP II at target promoters, as evidenced by ChIP analysis [25, 32, 33], suggesting potential recruitment of RNAP II by Ago proteins. However, biochemical evidence is missing. We showed a direct interaction of Ago2-loaded saRNAs with RNAP II, and the accumulation of initiating RNAP II at the p21 promoter and RNAP II Ser2P in gene body upon saRNA treatment. We thus conclude that RNAa of p21 causes an increase of both transcription initiation and transition to productive elongation.

Previous studies have shown that different epigenetic changes such as demethylation of H3K9 and dimethylation and trimethylation of H3K4 [13, 14, 24, 34] are associated with gene activation induced by saRNA. However, it is unclear whether such changes are the cause or
saRNA-Ago2 assembles RITA complex to induce transcription

...cellular and nuclear marker, respectively.

ChIP assay

ChIP assay was performed as previously described [32]. Briefly, chromatin was prepared from PC-3 cells following crosslinking with formaldehyde. DNA was sheared to an average size of ~500 bp using a Bioruptor sonicator (Diagenode). Chromatin was immunoprecipitated overnight at 4 °C using 5 µg of the following antibodies: anti-RNAPII (Millipore, cat #05-623), anti-RNAPII Ser2P (Abcam, cat #ab5095), anti-RNAPII Ser5P (Abcam, cat #ab5131). The following day, the samples were incubated with 25 µl Protein G Dynabeads (Invitrogen) for 2 h at 4 °C. Immunoprecipitates were sequentially washed with low salt, high salt, and TE buffer. Eluates were collected and reverse crosslinked at 65 °C overnight. ChIP DNA was treated with Proteinase K, purified with phenol/chloroform, treated with RNase A, and purified using the Qiaquick PCR purification kit (Qiagen). Target amplification and detection was performed on a 7500 Fast Real-Time System (Applied Biosystems). Enrichment was determined by using the 2–ΔΔCt method relative to input DNA or IgG control.
Competing Financial Interests

LCL is a named inventor on patents related to RNAa which have been licensed to MiNA Therapeutics, Ltd.

References

1. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130:77-88.
2. Nechaev S, Fargo DC, dos Santos G, Liu L, Gao Y, Adelman K. Global analysis of short RNAs reveals widespread promoter-proximal stalling and arrest of Pol II in Drosophila. Science 2010; 327:335-338.
3. Core LJ, Lis JT. Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science 2008; 319:1791-1792.
4. Buskirk AR, Kehayova PD, Landrigan A, Liu DR. In vivo evolution of an RNA-based transcriptional activator. Chem Biol 2003; 10:533-540.
5. Besch R, Giovannangeli C, Schuh T, Kammerbauer C, Degitz K. Characterization and quantification of triple helix formation in chromosomal DNA. J Mol Biol 2004; 341:979-989.
6. Kaihatsu K, Janowski BA, Corey DR. Recognition of chromosomal DNA by PnAs. Chem Biol 2004; 11:749-758.
7. Fire A, Xu S, Montgomery MK, Costas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-811.
8. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 2002; 297:1833-1837.
9. Zilberman D, Cao X, Jacobsen SE. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 2003; 299:716-719.
10. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004; 305:1289-1292.
11. Janowski BA, Huffman KE, Schwartz JC, et al. Inhibiting gene expression at transcription start sites in chromosomal DNA with antigenic siRNAs. Nat Chem Biol 2005; 1:216-222.
12. Kim DH, Villeneuve LM, Morris KV, Rossi JJ. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol 2006; 13:793-797.
13. Li LC, Okino ST, Zhao H, et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103:17337-17342.
14. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3:166-173.
15. Yin H, Lin H. An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster. Nature 2007; 450:304-308.
16. Shibuya K, Fukushima S, Takatsuji H. RNA-directed DNA methylation induces transcriptional activation in plants. Proc Natl Acad Sci USA 2009; 106:1660-1665.
17. Seth M, Shirayama M, Gu W, Ishidate T, Conte D, Jr, Mello CC. The C. elegans CSR-1 argonaute pathway counteracts epigenetic silencing to promote germline gene expression.
saRNA-Ago2 assembles RITA complex to induce transcription

Dev Cell 2013; 27:656-663.

Turner MJ, Jiao AL, Slack FJ. Autoregulation of lin-4 microRNA transcription by RNA activation (RNAa) in C. elegans. Cell Cycle 2014; 13:772-781.

Tolia NH, Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol 2007; 3:36-43.

Pal-Bhadra M, Leibovitch BA, Gandhi SG, et al. Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 2004; 303:669-672.

Verdel A, Jia S, Gerber S, et al. RNAi-mediated targeting of heterochromatin by the RITS complex. Science 2004; 303:672-676.

Place RF, Noonan EJ, Foldes-Papp Z, Li LC. Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol 2010; 11:518-526.

Huang V, Qin Y, Wang J, et al. RNAa is conserved in mammalian cells. PLoS One 2010; 5:e8848.

Turunen MP, Lehtola T, Heinonen SE, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanisms: a novel example of epigenetherapy. Circ Res 2009; 105:604-609.

Chu Y, Yue X, Younger ST, Janowski BA, Corey DR. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res 2010; 38:7736-7748.

Li LC. The multifaceted small RNAs. RNA Biol 2008; 5:61-64.

Wang J, Place RF, Huang V, et al. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res 2010; 70:10182-10191.

Wang X, Wang J, Huang V, Place RF, Li LC. Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation. Biochem J 2012; 443:821-828.

Kang MR, Yang G, Place RF, et al. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res 2012; 72:5069-5079.

Reebey V, Saetrom P, Mintz PJ, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 2014; 59:216-227.

Wang T, Li M, Yuan H, et al. saRNA guided iNOS up-regulation improves erectile function of diabetic rats. J Urol 2013.

Huang V, Place RF, Portnoy V, et al. Uregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012; 40:1695-1707.

Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008; 105:1608-1613.

Hu J, Chen Z, Xia D, Wu J, Xu H, Ye ZQ. Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation. Biochem J 2012; 447:407-416.

Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003; 9:1034-1048.

Chen PY, Weinmann L, Gaidatzis D, et al. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008; 14:263-274.

Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115:209-216.

Ahlenstiel CL, Lim HG, Cooper DA, Ishida T, Kelleher AD, Suzuki K. Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Res 2011.

Landthaler M, Gaidatzis D, Rothballer A, et al. Strand-specific Argonaute-containing mRNA-protein complexes and their bound target mRNAs. RNA 2008; 14:2580-2596.

Hock J, Weinmann L, Ender C, et al. Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells. EMBO Rep 2007; 8:1052-1060.

Ameyar-Zazoua M, Rachez C, Souidi M, et al. Argonate proteins couple chromatin silencing to alternative splicing. Nat Struct Mol Biol 2012; 19:998-1004.

Jain A, Bacolla A, Chakraborty P, Grosse F, Vasquez KM. Human DHX9 helicase unwinds triple-helical DNA structures. Biochemistry 2010; 49:6992-6999.

Huo L, Wang YN, Xia W, et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci USA 2010; 107:16125-16130.

Zhong X, Safa AR. RNA helicase A in the MEF1 transcription factor complex up-regulates the transcriptional coactivator. EMBO Rep 2005; 5:1626-275.

Meister G, Landthaler M, Peters L, et al. Identification of novel argonona-assocaited proteins. Curr Biol 2005; 15:2149-2155.

Schwartz JC, Younger ST, Nguyen NB, et al. Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol 2008; 15:842-848.

Zhang SS, Grosse F. Purification and characterization of two DNA helicases from calf thymus nucleus. J Biol Chem 1991; 266:20483-20490.

Tang W, You W, Shi F, et al. RNA helicase A acts as a bridging factor linking nuclear beta-actin with RNA polymerase II. Biochem J 2009; 420:421-428.

Myohanen S, Baylin SB. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J Biol Chem 2001; 276:1634-1642.

Tetsuka T, Uranishi H, Sanda T, et al. RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator. Eur J Biochem 2004; 271:3741-3751.

Zhong X, Safa AR. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells. J Biol Chem 2004; 279:17134-17141.

Aratani S, Fujii R, Oishi T, et al. Dual roles of RNA helicase A in CREB-dependent transcription. Mol Cell Biol 2001;
62 Kim J, Guermah M, Roeder RG. The human PAF1 complex
61 Zhang S, Grosse F. Molecular characterization of nuclear
59 Robb GB, Rana TM. RNA helicase A interacts with RISC in
58 Nakajima T, Uchida C, Anderson SF, et al. Small region of Rtf1 protein can substitute for complete Pafl complex in facilitating global histone H2B ubiquitination in yeast. Proc Natl Acad Sci USA 2012; 109:10837-10842.
57 Valineva T, Yang J, Silvennoinen O. Characterization of RNA helicase A as component of STAT6-dependent enhanceosome. Nucleic Acids Res 2006; 34:3938-3946.
56 Fujii R, Okamoto M, Atanasi S, et al. A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1. J Biol Chem 2001; 276:5445-5451.
55 Jaehning JA. The Paf1 complex: platform or player in RNA transcription elongation both independently and cooperatively with SII/TFIIS. Genes Dev 2011; 25:2254-2265.
54 Nakajima T, Uchida C, Anderson SF, et al. Molecular evidence indicating that the yeast PAF complex is required for transcription elongation. Mol Cell 2002; 10:483-488.
53 Rondon AG, Gallardo M, Garcia-Rubio M, Aguilera A. Molecular evidence indicating that the yeast PAF complex is required for transcription elongation. EMBO Rep 2004; 5:47-53.
52 Zhang Y, Sikes ML, Beyer AL, Schneider DA. The Pafl complex is required for efficient transcription elongation by RNA polymerase I. Proc Natl Acad Sci USA 2009; 106:2153-2158.
51 Mueller CL, Jaehning JA. Ctr9, Rtf1, and Leol are components of the Pafl/RNA polymerase II complex. Mol Cell Biol 2002; 22:1971-1980.
50 Kuroda MI, Kernan MJ, Kreber R, Ganetzky B, Baker BS. The maleless protein associates with the X chromosome to regulate dosage compensation in Drosophila. Cell 1991; 66:935-947.
49 Zhang S, Grosse F. Molecular characterization of nuclear DNA helicase II (RNA helicase A). Methods Mol Biol 2010; 587:291-302.
48 Kim J, Guermah M, Roeder RG. The human Pafl complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. Cell 2010; 140:491-503.
47 Muller CL, Jaehning JA. Ctr9, Rtf1, and Leol are components of the Pafl/RNA polymerase II complex. Mol Cell Biol 2002; 22:1971-1980.
46 Krogan NJ, Kim M, Ahn SH, et al. RNA polymerase II elongation factors of Saccharomyces cerevisiae: a targeted proteomics approach. Mol Cell Biol 2002; 22:6979-6992.
45 Rondon AG, Gallardo M, Garcia-Rubio M, Aguilera A. Molecular evidence indicating that the yeast PAF complex is required for transcription elongation. EMBO Rep 2004; 5:47-53.
44 Zhang Y, Sikes ML, Beyer AL, Schneider DA. The Pafl complex is required for efficient transcription elongation by RNA polymerase I. Proc Natl Acad Sci USA 2009; 106:2153-2158.
43 Jaehning JA. The Pafl complex: platform or player in RNA polymerase II transcription? Biochim Biophys Acta 2010; 1799:379-388.
42 Chu Y, Simic R, Warner MH, Arndt KM, Prelich G. Regulation of histone modification and cryptic transcription by the Burl and Pafl complexes. EMBO J 2007; 26:4646-4656.
41 Massonni-Laporte A, Perrot M, Ponger L, Boucherie H, Guieysse-Peugeot AL. Proteome analysis of a CTR9 deficient yeast strain suggests that Ctr9 has function(s) independent of the Pafl complex. Biochim Biophys Acta 2012; 1824:759-768.
40 Musso M, Bianchi-Scarra G, Van Dyke MW. The yeast CDP1 gene encodes a triple-helical DNA-binding protein. Nucleic Acids Res 2000; 28:4090-4096.
39 Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 2011; 44:667-678.
38 Strobl LJ, Eick D. Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo. EMBO J 1992; 11:3307-3314.
37 Battaglia P, Zhang Z, Yen K, Goffman DB, Pugh BF. Genome-wide function of H2B ubiquitination in promoter and generic regions. Genes Dev 2011; 25:2254-2265.
36 Minsky N, Shema E, Field Y, Schuster M, Segal E, Oren M. Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol 2008; 10:483-488.
35 van der Oost J. Molecular biology. New tool for genome surgery. Science 2013; 339:768-770.
34 Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol 2010; 17:1344-1355.
33 Zhang X, Li H, Burnett JC, Rossi J. The role of antisense long noncoding RNA in small RNA-triggered gene activation. RNA 2014; 20:1916-1928.
32 Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 2011; 44:667-678.